AM J MED GENET A:NF1会增加女性患乳腺癌风险

2012-11-30 AM J MED GENET A AM J MED GENET A

       约翰霍普金斯大学的一项研究显示,患有1型神经纤维瘤病(NF1)的妇女乳腺癌的发病率增加了4倍以上,越来越多的证据显示,患有这种罕见遗传性疾病的妇女可能会受益于早期乳腺癌筛查(40岁开始做乳房X光检查)和青春期乳房手检。        在约翰霍普金斯大学的综合神经纤维瘤病中心开展的一项纳入125例

       约翰霍普金斯大学的一项研究显示,患有1型神经纤维瘤病(NF1)的妇女乳腺癌的发病率增加了4倍以上,越来越多的证据显示,患有这种罕见遗传性疾病的妇女可能会受益于早期乳腺癌筛查(40岁开始做乳房X光检查)和青春期乳房手检。

       在约翰霍普金斯大学的综合神经纤维瘤病中心开展的一项纳入125例NF1女性患者的小规模研究中,研究人员发现了4例乳腺癌。该研究的结果显示,50岁以下的患有NF1的女性罹患乳腺癌的风险是一般人群的4倍。

       该研究除了对NF1女性患者应重视乳腺癌筛查的指导意义,也揭示了那些没有临床症状的乳腺癌的起源和性质,因为近期其他的研究表明,一些非NF1的女性因NF1基因突变而引发乳腺癌。发表在《自然》杂志上的一项研究显示,普通人群中,大约3%的乳腺癌是因为NF1基因突变而发生。

       目前对于有乳腺癌家族史或BRCA基因突变的乳腺癌高风险人群有相关指南,但是NF1女性患者以往未作为乳腺癌的高风险人群,还没有相关的指南。现在,我们越来越了解这个风险,医生应该告诉这类患者关于早期筛查的益处和危害。

       研究人员表示,该研究的主要意义是希望医学学会制定相关指南,让大家都知道50岁以下的NF1女性患者是乳腺癌的风险人群,从而指导临床实践。



Abstract
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder associated with increased risk for neoplasms. Two studies in the United Kingdom have indicated that women with NF1 (particularly women under 50) may also be at increased risk of breast cancer. No such study has been done to date in the United States. Chart review for breast cancer diagnoses was undertaken for 126 women with NF1 followed at Johns Hopkins who were 20 years of age or older. Four of 126 women who met eligibility criteria were diagnosed with breast cancer (3.2% over 15 years). The unadjusted standardized incidence ratio (SIR) for breast cancer in the NF1 population between the ages of 20 and 49 was 2.68 (P=0.076, 95% CI 0.68–7.29) based on incidence rates of breast cancer in the general population taken from the Surveillance Epidemiology and End Results (SEER) database. The unadjusted SIR for women with NF1 ≥50 was 0.81 (P=0.84, 95% CI 0.041–4.01). When adjusted for race, the rate of NF1 in the general population and time of diagnosis, the SIR was 4.41 (P=0.0049, 95% CI 1.12–12.00) for women <50 versus 0.94 (P=0.95, 95% CI 0.047–4.65) for women ≥50. The trend of a higher-than-expected number of breast cancer cases in women <50 with NF1 agrees with the prior studies from the literature. Cumulatively, the data suggests an increased risk of breast cancer for women with NF1<50 years old, implying a need for closer surveillance and the establishment of screening guidelines for this patient population. © 2012 Wiley Periodicals, Inc.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
    2013-09-20 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
    2013-05-26 ay2000fy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1685872, encodeId=69c516858e2b4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Apr 01 01:00:00 CST 2013, time=2013-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770205, encodeId=7cff1e70205da, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu May 30 18:00:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061356, encodeId=1ddd20613564d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 18:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733612, encodeId=7ed31e33612a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Sep 20 21:00:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927975, encodeId=93cd192e975b4, content=<a href='/topic/show?id=ed8712e399b' target=_blank style='color:#2F92EE;'>#NF1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12739, encryptionId=ed8712e399b, topicName=NF1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Sun May 26 16:00:00 CST 2013, time=2013-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605858, encodeId=6d2c1605858c3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 01 15:00:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048484, encodeId=ad4620484844a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 31 01:00:00 CST 2013, time=2013-03-31, status=1, ipAttribution=)]
    2013-03-31 cy0324